1800 202 8726
After your biopsy result

After a Positive Prostate Biopsy, — What Happens Next?

A positive result is the start of a staging process that leads to a treatment plan built around your specific cancer — not prostate cancer in general.

Medically reviewed by Dr. Mohammed Imaduddin, Surgical Oncologist, MBBS · MS (General Surgery) · M.Ch (Surgical Oncology) · Last reviewed September 2026

  • Grade is what matters most — Your Grade Group — not the diagnosis alone — determines your treatment pathway and whether active surveillance is an option.
  • Staging before deciding — For intermediate and high-risk disease, a PSMA PET-CT is arranged before any recommendation is finalised.
  • Surveillance is a real option — For selected low-risk cases, active monitoring rather than immediate treatment is recommended by NCCN and ESMO guidance.
  • You have time to ask — Treatment decisions are not made on the day of your result. The MDT process gives you time to understand each option fully.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Get this explained properly

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

A positive biopsy confirms cancer cells are present in your prostate. What happens next depends on your Grade Group and PSA level, not the result alone. For low-grade disease, active surveillance is often the right next step. For intermediate or high-grade disease, staging scans — including PSMA PET-CT — are arranged before any treatment decision.

What does a positive result actually mean?

A positive biopsy means cancer cells were found in your prostate tissue. It does not tell you, by itself, whether those cells need immediate treatment.

What matters most is the grade. Your PSA level, Grade Group and clinical stage together determine your risk group — and that risk group determines what happens next. A low-grade cancer found in one or two cores behaves very differently from a high-grade cancer present across most of the gland.

What are the next steps after your result?

Your result is reviewed by a multidisciplinary team — urologists, radiation oncologists, medical oncologists and radiologists — following NCCN and ESMO guidance on standard practice.

If your Grade Group or PSA places you in the intermediate or high-risk category, staging scans are arranged. PSMA PET-CT is now preferred by ASCO and ESMO for detecting spread in higher-risk localised prostate cancer, as it is more sensitive than conventional imaging. For low-risk disease, scans are often not needed before treatment options are discussed.

You will not be asked to decide on treatment at your next appointment. That meeting is for explaining options and answering questions.

Terms you will hear in the next few weeks

Grade Group
The current grading system for prostate cancer, rated 1 to 5. Grade Group 1 — previously called Gleason 6 — is the least aggressive pattern; Grade Group 5 is the most aggressive. Assigned by the pathologist from your biopsy tissue.
PSMA PET-CT
A scan that detects prostate-specific membrane antigen on cancer cells more accurately than conventional CT and bone scan. ASCO and ESMO recommend it as the preferred staging investigation for intermediate and high-risk prostate cancer.
Risk group
A classification — low, intermediate, high, very high — combining PSA level, Grade Group and clinical stage. It determines which treatment options your team will discuss with you.
Active surveillance
Structured monitoring — regular PSA tests, MRI and repeat biopsies at set intervals — rather than immediate treatment. NCCN recommends it for Grade Group 1 disease and selected Grade Group 2 cases.

Still unclear?

Send your reports across and a specialist will walk you through what they mean — what is known, what is not, and what the options actually are.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

Get a straight answer from a specialist

45 minutes, your reports reviewed, your questions answered in plain language.

Book Free Consultation Call 1800 202 8726

What the process looks like over the coming weeks

  1. Pathology reviewed

    Your biopsy cores are graded by a pathologist who assigns a Grade Group and reports how many cores were involved. Your treating team reviews this report before advising on next steps.

  2. Staging scans if indicated

    For intermediate and high-risk disease, a PSMA PET-CT is coordinated through a partner imaging centre. For low-risk disease, scans are often not needed before treatment options are discussed.

  3. Multidisciplinary team meeting

    Your case is presented to the MDT — urological surgery, radiation oncology, medical oncology and radiology — who reach a recommendation together before it is brought to you.

  4. Consultation and shared decision

    Your oncologist or urologist explains the recommendation and the alternatives. You have time to ask about side effects and what each option aims to achieve before any decision is made.

Did you know?

PSMA PET-CT detects prostate cancer spread more accurately than conventional CT and bone scan combined — changing the staging picture, and therefore the treatment plan, for a meaningful proportion of intermediate and high-risk patients who have it done.

ASCO and ESMO now recommend it as the preferred staging investigation for higher-risk localised prostate cancer where it is available.

Source: ASCO and ESMO Clinical Practice Guidelines on Prostate Cancer Staging

Your treatment options explained

Is active surveillance safe — will waiting let the cancer spread?

Active surveillance is not waiting and hoping. It is a structured programme with regular PSA tests, MRI and repeat biopsies at defined intervals, and a clear plan to treat if the cancer progresses. NCCN recommends it for Grade Group 1 disease and selected Grade Group 2 cases. The evidence shows monitoring does not worsen long-term outcomes for carefully selected patients, while avoiding the side effects of immediate treatment. Your oncologist will confirm whether you meet the criteria.

What does surgery involve and what are the side effects?

Radical prostatectomy removes the prostate gland and surrounding tissue. It is offered for localised disease and some locally advanced cases. Side effects your surgeon will discuss include urinary incontinence — which improves substantially for most men over months — and erectile dysfunction, which depends on whether the nerve bundles alongside the prostate can be preserved. Your surgeon will explain what is technically possible in your individual case before you decide.

What does radiation therapy involve?

Radiation for prostate cancer can be external beam, brachytherapy — seeds or a high-dose implant placed inside the prostate — or a combination of both. It is an alternative to surgery for localised disease and the preferred approach for locally advanced disease, usually combined with hormone therapy. NCCN and ESMO recommend the combination for intermediate and high-risk cases. The main side effects — urinary irritation and bowel changes — differ from those of surgery.

What is hormone therapy and when is it used?

Hormone therapy reduces testosterone, which prostate cancer cells depend on to grow. For localised and locally advanced disease it is almost always combined with radiation rather than used alone. For metastatic disease it forms the backbone of treatment, usually alongside other systemic agents. NCCN, ASCO and ESMO recommend the combined approach for intermediate and high-risk localised disease. Side effects include hot flushes, fatigue and bone density loss over time.

What if staging shows the cancer has already spread?

If spread to lymph nodes or bones is confirmed on staging, systemic treatment rather than local treatment alone becomes the focus. Established combinations of hormone therapy with other systemic agents have improved outcomes in metastatic prostate cancer and are reviewed regularly by NCCN and ESMO. Your oncologist will explain what spread means specifically in your case and what treatment is intended to achieve.

Explore 133 more Biopsy by Body Part topics

HUB — Biopsy by Body Part

All Biopsy by Body Part →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Do I need a PSMA PET scan?

Whether you need one depends on your risk group. ASCO and ESMO recommend PSMA PET-CT for intermediate and high-risk disease, where it detects spread more accurately than conventional imaging. For low-risk disease it is generally not indicated before the treatment discussion. Your oncologist will tell you whether it applies to your result, and coordinate it through a partner imaging centre if it does.

Is active surveillance really safe — or will waiting let the cancer spread?

For men who meet the clinical criteria, active surveillance is a recommended approach, not a gamble. NCCN supports it for Grade Group 1 and selected Grade Group 2 cases. The structured monitoring — regular PSA, MRI and repeat biopsies — means any progression is detected early and treatment can be started promptly. The evidence shows it does not worsen long-term outcomes for carefully selected patients compared with immediate treatment.

What is the difference between a Gleason 6 and a Gleason 7?

Gleason 6 — now Grade Group 1 — means cells that look close to normal under the microscope. It is the lowest grade and most often managed with active surveillance. Gleason 7 covers Grade Group 2 and Grade Group 3, which behave differently from each other. A Gleason 3+4 is Grade Group 2; a Gleason 4+3 is Grade Group 3. The dominant pattern — the first number — matters significantly, which is why your team refers to the Grade Group specifically.

How long do I have before I need to decide on treatment?

For most prostate cancers, you have weeks rather than days to decide. Prostate cancer typically progresses slowly enough that taking the time to understand your options is the right approach, not a risk. Your team will tell you if there is a clinical reason to move faster in your specific case. Use the time to ask questions, and if you want one, seek a second opinion — speaking with both a urologist and a radiation oncologist before deciding is entirely reasonable.

What questions should I ask at my next appointment?

Ask four things: what is my Grade Group and risk group; am I a candidate for active surveillance; do I need a PSMA PET-CT; and what are the main side effects of the options being recommended, and how often do they occur. Write the answers down — these consultations are hard to remember accurately afterwards. Bringing someone with you to take notes is always welcome, and asking for the key points in writing is a reasonable request.

Is prostate cancer treated at CION?

Yes. Prostate cancer treatment — including radiation therapy and systemic treatments such as hormone therapy — is delivered at CION centres. If a PSMA PET-CT is indicated for staging, it is coordinated with a partner imaging centre. CION does not provide CAR-T or cell therapy; if that is being considered as part of a specialised or trial pathway, you would be referred to a centre that offers it.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation